$ACAD
ACADIA PHARMACEUTICALS INC

2024 Q2 Form 10-Q Financial Statement

#000095017024056077 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $242.0M $205.8M
YoY Change 46.44% 73.75%
Cost Of Revenue $18.23M $22.95M
YoY Change 144.4% 1276.78%
Gross Profit $223.7M $182.9M
YoY Change 41.8% 56.58%
Gross Profit Margin 92.47% 88.85%
Selling, General & Admin $117.1M $108.0M
YoY Change 21.98% 6.67%
% of Gross Profit 52.32% 59.05%
Research & Development $76.23M $59.68M
YoY Change 29.71% -13.69%
% of Gross Profit 34.07% 32.63%
Depreciation & Amortization $2.571M $242.0K
YoY Change 45.58% -43.19%
% of Gross Profit 1.15% 0.13%
Operating Expenses $193.3M $167.7M
YoY Change 24.92% -1.59%
Operating Profit $30.44M $15.21M
YoY Change 902.21% -128.39%
Interest Expense $6.359M $5.506M
YoY Change 39.76% 44.89%
% of Operating Profit 20.89% 36.2%
Other Income/Expense, Net $386.0K $286.0K
YoY Change -131.03% -94.1%
Pretax Income $37.20M $21.00M
YoY Change 486.47% -146.77%
Income Tax $3.800M $4.400M
% Of Pretax Income 10.22% 20.95%
Net Earnings $33.39M $16.56M
YoY Change 2897.22% -138.48%
Net Earnings / Revenue 13.8% 8.04%
Basic Earnings Per Share $0.20 $0.10
Diluted Earnings Per Share $0.20 $0.10
COMMON SHARES
Basic Shares Outstanding 165.2M 164.8M
Diluted Shares Outstanding 166.2M 166.6M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $500.9M $470.5M
YoY Change 33.45% 16.79%
Cash & Equivalents $177.1M $204.7M
Short-Term Investments $323.8M $265.8M
Other Short-Term Assets $46.06M $42.76M
YoY Change 92.74% 80.95%
Inventory $86.07M $66.64M
Prepaid Expenses $46.06M $42.76M
Receivables $103.7M $94.70M
Other Receivables $6.695M $5.378M
Total Short-Term Assets $728.9M $675.3M
YoY Change 47.96% 34.29%
LONG-TERM ASSETS
Property, Plant & Equipment $4.144M $4.370M
YoY Change -92.8% -21.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $476.0K $476.0K
YoY Change -98.04% -96.17%
Total Long-Term Assets $185.2M $179.8M
YoY Change 23.34% 17.94%
TOTAL ASSETS
Total Short-Term Assets $728.9M $675.3M
Total Long-Term Assets $185.2M $179.8M
Total Assets $914.1M $855.1M
YoY Change 42.21% 30.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.88M $19.33M
YoY Change 5.69% 10.96%
Accrued Expenses $318.0M $311.3M
YoY Change 88.0% 50.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $337.9M $330.6M
YoY Change 79.76% 47.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.36M $11.27M
YoY Change -79.06% 112.5%
Total Long-Term Liabilities $12.36M $11.27M
YoY Change -79.06% 112.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $337.9M $330.6M
Total Long-Term Liabilities $12.36M $11.27M
Total Liabilities $397.4M $391.1M
YoY Change 60.91% 39.14%
SHAREHOLDERS EQUITY
Retained Earnings -$2.381B -$2.414B
YoY Change -1.27% 0.07%
Common Stock $2.898B $2.879B
YoY Change 3.21% 3.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $516.7M $464.0M
YoY Change
Total Liabilities & Shareholders Equity $914.1M $855.1M
YoY Change 42.21% 30.49%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $33.39M $16.56M
YoY Change 2897.22% -138.48%
Depreciation, Depletion And Amortization $2.571M $242.0K
YoY Change 45.58% -43.19%
Cash From Operating Activities $25.01M $29.08M
YoY Change 205.0% -262.15%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$56.19M -$14.04M
YoY Change -63.58% -107.29%
Cash From Investing Activities -$56.19M -$14.04M
YoY Change -71.08% -107.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.565M 1.043M
YoY Change -34.92% -28.85%
NET CHANGE
Cash From Operating Activities 25.01M 29.08M
Cash From Investing Activities -56.19M -14.04M
Cash From Financing Activities 3.565M 1.043M
Net Change In Cash -27.61M 16.09M
YoY Change -84.71% -90.86%
FREE CASH FLOW
Cash From Operating Activities $25.01M $29.08M
Capital Expenditures $0.00
Free Cash Flow $25.01M
YoY Change -178.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-50768
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
06-1376651
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12830 El Camino Real
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
558-2871
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
ACAD
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
165220884
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204745000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188657000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
265775000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
250208000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
94701000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
98267000
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
5378000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
4083000
CY2024Q1 acad Short Term Inventory
ShortTermInventory
61936000
CY2023Q4 acad Short Term Inventory
ShortTermInventory
35819000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
42761000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
39091000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
675296000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
616125000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4370000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4612000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54280000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
51855000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
110204000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
65490000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2024Q1 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4707000
CY2023Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4628000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
476000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
476000
CY2024Q1 us-gaap Assets
Assets
855103000
CY2023Q4 us-gaap Assets
Assets
748956000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
19332000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17543000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
311265000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
236711000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
330597000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
254254000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49189000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47800000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11273000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
15147000
CY2024Q1 us-gaap Liabilities
Liabilities
391059000
CY2023Q4 us-gaap Liabilities
Liabilities
317201000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
164959736
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164959736
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
164650219
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164650219
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2878539000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2862552000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2414282000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2430837000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-229000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
464044000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
431755000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
855103000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
748956000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
205831000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
118462000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
205831000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
118462000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
22951000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1667000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59679000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69144000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
107991000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
101235000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
190621000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
172046000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
15210000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-53584000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5506000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3800000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
286000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4845000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21002000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44939000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4447000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1918000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
16555000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43021000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.1
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
164798000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162263000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166623000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
162263000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
16555000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43021000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-258000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
757000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
16302000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42266000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
16555000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-43021000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194427000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120616000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210515000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14750000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14705000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1786000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2267000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5286000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
4845000
CY2024Q1 acad Loss On Sale Of Investment Securitie
LossOnSaleOfInvestmentSecuritie
0
CY2023Q1 acad Loss On Sale Of Investment Securitie
LossOnSaleOfInvestmentSecuritie
505000
CY2024Q1 us-gaap Depreciation
Depreciation
242000
CY2023Q1 us-gaap Depreciation
Depreciation
426000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3566000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3720000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
1295000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
3450000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
16648000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-481000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3670000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2234000
CY2024Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1759000
CY2023Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1726000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1789000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4676000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12193000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
24510000
CY2024Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
212000
CY2023Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1656000
CY2024Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3874000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3769000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29079000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17933000
CY2024Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
80154000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
66892000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
66115000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
259410000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14039000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
192518000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1043000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1466000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1043000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1466000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16088000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
176049000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
296665000
CY2024Q1 acad Accrued Inventory Purchases
AccruedInventoryPurchases
9354000
CY2023Q1 acad Accrued Inventory Purchases
AccruedInventoryPurchases
0
CY2024Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
50000000
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
69583000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
431755000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
400413000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
464044000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
374258000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188657000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204745000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114846000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
290895000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194427000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210515000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120616000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
296665000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15081000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20764000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
205831000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
118462000
CY2024Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
16555000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
16555000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43021000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-43021000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
164798000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162263000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166623000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
162263000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.1
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14750000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14705000
CY2024Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7576000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5001000
CY2024Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5549000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4134000
CY2024Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
53518000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
31312000
CY2024Q1 us-gaap Inventory Net
InventoryNet
66643000
CY2023Q4 us-gaap Inventory Net
InventoryNet
40447000
CY2024Q1 acad Short Term Inventory
ShortTermInventory
61936000
CY2023Q4 acad Short Term Inventory
ShortTermInventory
35819000
CY2024Q1 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4707000
CY2023Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4628000
CY2024Q1 us-gaap Inventory Net
InventoryNet
66643000
CY2023Q4 us-gaap Inventory Net
InventoryNet
40447000
CY2024Q1 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
122436000
CY2023Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
90718000
CY2024Q1 acad Accrued Contingent Payments
AccruedContingentPayments
79583000
CY2023Q4 acad Accrued Contingent Payments
AccruedContingentPayments
29583000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26061000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42718000
CY2024Q1 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
23878000
CY2023Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
32883000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
19684000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
18804000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10453000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9405000
CY2024Q1 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
7836000
CY2023Q4 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
718000
CY2024Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
7591000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
8710000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13743000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3172000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
311265000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
236711000
CY2024Q1 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
266007000
CY2024Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
10000
CY2024Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
242000
CY2024Q1 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
265775000
CY2023Q4 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
250182000
CY2023Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
166000
CY2023Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
140000
CY2023Q4 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
250208000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
30
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
21
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
222487000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
242000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
222487000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
242000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
149953000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
140000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
149953000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
140000
CY2024Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
317651000
CY2024Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
200000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
314794000
CY2023Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
4506000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4506000
CY2024Q1 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Vesting Of Awards
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVestingOfAwards
-142000
CY2024Q1 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Forfeited
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseForfeited
-117000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-4047000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
200000
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
15100000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
4400000
CY2024Q1 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
9900000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
200000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
4300000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
300000
CY2024Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
50000000
CY2024Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 0.7 years to 7.2 years, some of which include options to extend for up to two five-year terms.
CY2024Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
some of which include options to extend for up to two five-year terms.
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2810000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2181000
CY2024Q1 us-gaap Sublease Income
SubleaseIncome
286000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
0
CY2024Q1 us-gaap Lease Cost
LeaseCost
2524000
CY2023Q1 us-gaap Lease Cost
LeaseCost
2181000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2405000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2370000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4184000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
304000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10453000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9405000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49189000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47800000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
59642000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
57205000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8067000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
10818000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10182000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9940000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9520000
CY2024Q1 acad Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
20606000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
69133000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9491000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
59642000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.047
CY2020Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
40300000
CY2021Q1 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
19200000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4400000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21000000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1900000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44900000
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.2117
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.0427
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-056077-index-headers.html Edgar Link pending
0000950170-24-056077-index.html Edgar Link pending
0000950170-24-056077.txt Edgar Link pending
0000950170-24-056077-xbrl.zip Edgar Link pending
acad-20240331.htm Edgar Link pending
acad-20240331.xsd Edgar Link pending
acad-ex10_1.htm Edgar Link pending
acad-ex10_2.htm Edgar Link pending
acad-ex10_3.htm Edgar Link pending
acad-ex31_1.htm Edgar Link pending
acad-ex31_2.htm Edgar Link pending
acad-ex32_1.htm Edgar Link pending
acad-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img91857729_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
acad-20240331_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending